Connect with us

Technology

Guardian launches GuardianWell™, a new digital hub designed to enhance benefits utilization and inspire well-being®

Published

on

With half of employers looking to improve workforce understanding of benefits, GuardianWell will enhance benefits utilization by offering relevant wellness education and streamlined access to benefits

NEW YORK, Oct. 9, 2024 /PRNewswire/ — The Guardian Life Insurance Company of America® (Guardian) is announcing the launch of GuardianWell™, its new digital well-being hub for Group Benefits members.

A centerpiece of Guardian’s mission to inspire well-being®, GuardianWell provides members with a single self-service online hub where they can engage with their wellness benefits and access educational content on mental, physical, and financial well-being, as well as on family and community support topics.

GuardianWell offers members a personalized experience based on their participation in Guardian’s various wellness offerings. For all eligible benefits, members can learn more about services provided and how they can start to utilize and make the most of these wellness resources. Wellness offerings integrated into the platform include caregiver support services through Wellthy, a digital substance use management program for tobacco cessation through Pelago, cancer support services via Osara Health, dedicated mental wellness benefits from Spring Health, and employee assistance programs.

Guardian continues to build on its record of innovation and was one of the first carriers to build caregiver and cancer support within its long-term disability insurance product and include tobacco cessation services in dental insurance offerings. GuardianWell is designed to help members access, understand, and use this expanded suite of wellness benefits.

According to recent research from Guardian, both employers and employees say there is a critical need for enhanced benefits communication and education. Less than half of employees (45%), for example, say that their employer does a good job of educating them about available benefits. Employers feel similarly, with just half saying they are confident that their employees understand their benefits. Additionally, 51% of employers said they would be interested in a single platform through which all wellness-related benefits could be made available. With workplace benefits playing an influential role in supporting employee well-being, closing this education and utilization gap is essential. 

“Employers and employees agree that workplace benefits play an important role in supporting a happy, healthy, and productive workforce,” said Jonathan Mayhew, Head of Group Benefits at Guardian. “We are excited to launch GuardianWell to offer a one-stop-digital-hub to enhance understanding of wellness resources, drive utilization, and help our members take care of themselves and their families.”

To ensure members can get the most out of their benefits, GuardianWell will have single sign-on integration with Guardian Anytime, Guardian’s employee benefits online service portal.

The launch of GuardianWell coincides with other efforts by Guardian to support well-being, including:

Ensuring a simple and clear path to accessing benefits during major life events, including an employee’s maternity journey. Across family planning and education, pregnancy, maternity leave, and return to work, members have access to a range of coordinated benefits and services. This includes fertility benefits through Guardian’s critical illness insurance, estate and will preparation assistance through employee assistance programs, caregiving support and mental health services to support work-life balance, and access to short-term disability riders that can include coverage for adoption and paternity leave, as well as coverage to ensure new moms receive their benefits from day one. During it all, employees are supported by case managers who are prepared to provide comprehensive, empathetic support.The development of an exclusive pet wellness offering to support pet parents. Guardian Group Benefits customers can elect to purchase a voluntary pet wellness benefit through Wagmo, which provides reimbursement for preventive and routine pet care expenses. With no restrictions for pet age, breed, or pre-existing conditions for all cats and dogs, there are no waiting periods or deductibles, and reimbursements are paid within 24 hours. The benefit also includes innovative telehealth services through VETalk, which provides pet owners with 24-hour access to a veterinary professional through text and video chat.

Initially available to new members with access to Guardian’s caregiving support services through Wellthy, Guardian plans to expand GuardianWell’s ecosystem and access to more members throughout 2025. More information can be found at https://www.guardianlife.com/group/guardianwell.

Media Contact
mediarelations@glic.com

About Guardian
Guardian makes a difference in the lives of people when they need us most. With over 160 years of stability and fiscal integrity, we are a trusted resource to generations of families and business owners, inspiring well-being and helping build financial confidence. Today, we stand behind millions of consumers, helping them prepare and plan for a bright future for themselves and their families. We help business owners care for their employees. And we help people recover and thrive in times of unexpected loss. As a modern mutual insurance company, we believe in driving value beyond dividends. We invest in our colleagues, are building an inclusive and innovative culture, and are helping to uplift communities through thoughtful corporate impact programs. Guardian, which is based in New York City, is a leading provider of life, disability, dental, and other benefits, and has received accolades for its culture and service. Our colleagues and financial professionals serve with care and experience, and our commitments rest on a strong financial foundation, which included a 2024 dividend allocation of $1.398 billion – the largest in the company’s history. For more information, visit guardianlife.com or follow us on FacebookLinkedIn, and YouTube.

Disclaimer
Guardian® is a registered trademark of The Guardian Life Insurance Company of America. Copyright © 2024 The Guardian Life Insurance Company of America.

Dividends are not guaranteed. They are declared annually by Guardian’s Board of Directors. The total dividend calculation includes mortality experience and expense management as well as investment results.

Financial information concerning Guardian as of December 31, 2023, on a statutory basis: Admitted assets = $80.3 billion; liabilities = $71.2 billion (including $58.0 billion of reserves); and surplus = $9.1 billion.

Guardian’s Short Term Disability is underwritten and issued by The Guardian Life Insurance Company of America, New York, NY. Products are not available in all states. Policy limitations and exclusions apply. Optional riders and/or features may incur additional costs. This policy provides disability income insurance only. It does NOT provide basic hospital, basic medical, or major medical insurance as defined by the New York State Department of Financial Services.

Wellthy, Inc. (“Wellthy”) is a vendor to The Guardian Life Insurance Company of America (“Guardian”). Wellthy and Guardian are not affiliated entities. Wellthy provides a dedicated care coordinator to integrate separately retained caregiver resources (e.g., senior care, childcare, etc.) for the benefit of a member and Wellthy permitted dependents/relatives (“Services”). Guardian does not control or provide any part of the Services and does not bear any liability for their provision. This informational resource is not a contract and is for illustrative purposes only. Only the policy contains applicable terms. Guardian and Wellthy reserve the right to discontinue Services at any time without notice. Services may not be available in all states. ©2024 The Guardian Life Insurance Company of America.

Osara Health (“Osara”) is a vendor to The Guardian Life Insurance Company of America (“Guardian”). Osara and Guardian are not affiliated entities. Osara provides a personalized support program through certified health coaches to address cancer management issues for the benefit of a member (“Services”). Services are designed for members 18 years+ of age, diagnosed with cancer, regardless of cancer type, stage, or prognosis. Services are not meant to provide medical advice/care. Medical advice/care should be sought from your independent healthcare provider(s). Guardian does not control or provide any part of the Services and does not bear any liability for their provision. Guardian and Osara reserve the right to discontinue Services at any time without notice. Services may not be available in all states.

Tobacco Cessation benefits discussed herein are provided by Pelago (Pelago Benefits). Pelago is not a medical care provider. The Guardian Life Insurance Company of America (Guardian) does not control or provide any part of the Pelago Benefits and does not bear any liability for their provision. This informational resource is not a contract and is for illustrative purposes only. Only the policy contains applicable terms. Pelago Benefits may not be available in all states. Guardian and Pelago reserve the right to discontinue the Pelago Benefits at any time without notice.

Mental wellness benefits discussed herein are provided by Spring Care, Inc., d/b/a Spring Health (“Spring Health”), 60 Madison Avenue, Floor 2, New York, NY 10010. Spring Health is not an insurance benefit. Insured products are offered by The Guardian Life Insurance Company, New York, N.Y. (“Guardian”) which has a financial interest in Spring Health.

Pet wellness benefits discussed herein are solely provided by Wagmo, Inc. (Wagmo). Pet wellness and VETalk are not insurance benefits. Reimbursement is subject to a maximum annual limit as outlined in the wellness benefit agreement. Guardian® is solely a distributor of Wagmo’s pet wellness benefits. Wagmo delivers and administers its own products/services. Guardian assumes no responsibility for Wagmo products/services. Wagmo is a registered service mark and registered trademark and is used with express permission.

View original content to download multimedia:https://www.prnewswire.com/news-releases/guardian-launches-guardianwell-a-new-digital-hub-designed-to-enhance-benefits-utilization-and-inspire-well-being-302270776.html

SOURCE Guardian

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

Connatix and JW Player Merge To Create the Industry’s Largest Video Technology and Monetization Platform

Published

on

By

Advanced offering brings unparalleled monetization and streaming capabilities across CTV and OLV for broadcasters, publishers, and advertisers

NEW YORK, Oct. 9, 2024 /PRNewswire/ — JW Player (JWP), the leading video streaming and data insights platform, today announced it is merging with Connatix, the leading video delivery and monetization solution, forming JWP Connatix. By unifying JWP’s broadcast-level live and on-demand streaming, data, and workflow capabilities with Connatix’s full stack advertising and content technology, JWP Connatix becomes the industry’s most comprehensive independent video technology and monetization platform for broadcasters, publishers, and advertisers.

This merger arrives as the digital video ecosystem is experiencing transformational change. Consumers are increasingly cutting the cord in favor of Connected TV (CTV) and streaming services, leading to rapid shifts in global advertising spend and the emergence of new direct-to-consumer subscription and pay-per-view offerings. In 2024, global CTV ad revenue will surpass $30 billion, while the top ten streaming services alone will support nearly 1 billion subscribers. Given this, publishers, broadcasters, and advertisers must transform their video strategies to meet these evolving viewer expectations and business needs.

“How and where viewers consume video is rapidly changing. As a result, media companies require innovative solutions that allow them to maximize audience engagement and help optimize revenue across disparate monetization models, whether it be advertising, subscriptions or commerce,” said David Kashak, Co-founder and CEO of Connatix. “Together, JWP Connatix fulfills that requirement, by accelerating our companies’ mutual visions to create environments where premium video viewing, powered by best-in-class technology, meets high-quality monetization experiences, enabling media leaders to deliver exceptional results.”

JWP Connatix creates an indispensable partner in this rapidly changing video ecosystem, powering streaming for over 2,000 blue-chip media companies, including 80% of the top 25 Comscore US publishers. As the largest independent global video network across CTV and OLV, the company reaches over 1 billion unique users and delivers 30 billion+ combined video plays and ad impressions every month. Key benefits for customers include: 

Global reach and reliable scale: Streaming 7 billion minutes of VOD and live content to over 1 billion unique users on any screen around the worldHybrid monetization models: Support for subscription, advertising and e-commerce business models, leveraging insights from content and audiences to help maximize revenueUnique insights to optimize outcomes: Leverage AI to combine trillions of contextual, consumption, and monetization data signals to match customers with content and ads, boosting engagementSingle end-to-end platform for OLV and CTV: Streamlined video management platform enabling diverse monetization opportunities across content, commerce, and creative

“By joining forces, JWP Connatix ushers in a new era for digital video. The complementary nature of our  businesses enables us to bring a unique combination of scale, product breadth, and industry expertise to the market,” added Dave Otten, CEO and Co-Founder of JWP. “Perhaps more importantly, we are bringing together two knowledgeable, and dedicated teams, whose skill-sets and values are a perfect match. We could not be more excited about this partnership and look forward to shaping the future of digital video together.”

As part of the transaction, Dave Otten will become CEO of the combined company, while David Kashak will serve as its Chairman. JWP Connatix will be headquartered in New York City with additional offices in London, Cluj-Napoca, Eindhoven, Skopje, and Tel Aviv.

About Connatix

Connatix is a video technology company that powers the world’s stories with effortless and inspiring solutions. Through a proprietary full-stack platform, Connatix helps publishers deliver, monetize, analyze and create video, while providing advertisers with premium video inventory and a collection of data intelligence solutions including Deep Contextual™and predictive audience targeting.  Sitting at the forefront of innovation, Connatix leverages the power of AI to optimize revenue and ensure relevancy, efficiency and scale across campaigns.

Connatix currently works with 350+ publisher groups across thousands of sites and leading brands and agencies. The private equity-backed business has been named an AdExchanger Programmatic Power Player for two consecutive years and included on the Inc. 5000 list of the fastest growing companies for three consecutive years. Founded in 2014, Connatix is headquartered in New York City and continues to expand its global footprint with offices in London, Cluj-Napoca, and Tel Aviv.

About JWP

JW Player (JWP) is a leader in video streaming and player technology, providing broadcasters and publishers with a platform for delivering and monetizing video content across web, OTT, CTV, and FAST platforms. JWP’s technology helps deliver exceptional video experiences, engage audiences, and increase viewing time. Pioneering innovations like HLS streaming, header bidding for video, and contextual content recommendations, JWP offers a comprehensive end-to-end streaming management platform. Founded in 2008, JWP is one of the fastest growing SaaS companies in the world with a vision to power video-driven businesses so they thrive in the digital video economy.  Serving over 2,000 global broadcasters, publishers, and video-driven brands, JWP powers video for over 1 billion users each month and 5 billion minutes of video watched. Headquartered in New York, JWP has offices in London, Eindhoven, and Skopje.

Media Contact
Cassady Nordeen
cassady@purposenorthamerica.com

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/connatix-and-jw-player-merge-to-create-the-industrys-largest-video-technology-and-monetization-platform-302271377.html

SOURCE Connatix

Continue Reading

Technology

Proteotype Awarded £1.5 Million Grant to Advance Early Cancer Detection with Innovative Enlighten® Test

Published

on

By

CAMBRIDGE, United Kingdom, Oct. 9, 2024 /PRNewswire/ — Proteotype Diagnostics Ltd, in collaboration with the University of Southampton, has been awarded £1.5 million in funding from the National Institute for Health and Care Research (NIHR) and the Office for Life Sciences (OLS). The grant (NIHR207538) will support clinical validation of Proteotype’s novel Enlighten® Multi-Cancer Early Detection test, a revolutionary approach to detecting early-stage cancers by focusing on the body’s response to tumour development.

A Breakthrough in Early Cancer Detection

While many cancer diagnostics rely on tumour-released signals, such as circulating tumour DNA, which is often only detectable once cancer has progressed, Enlighten® takes a different and potentially more powerful approach. It measures the host response to tumour development, tracking changing levels of proteins that occur even in the earliest stages of cancer.

Initial results have been promising. At AACR 2024, Proteotype reported a detection rate of 86% across multiple cancers, with a 0% false-positive rate and strong signals for early-stage cancers. The test now needs to be validated in a larger group of patients, enabling a statistically powered calculation of performance.

Dr. Emma Yates, co-founder and Chief Scientific Officer at Proteotype Diagnostics, said: “When cancer is discovered earlier, patients have more treatment options and better outcomes. Enlighten® is designed to disrupt, detecting cancer as early as the immune system, whilst remaining simple enough yet robust enough to fit existing care pathways and NHS needs.”

Focused on Health Equity

Enlighten® will be trialled in real-world NHS settings with a specific focus on reaching higher-risk, underserved populations. The MODERNISED clinical study, led by Professor Andrew Davies from the University of Southampton Experimental Cancer Medicine Centre, will recruit 1,350 participants across Southern England, targeting cancers with high mortality rates in socio-economically deprived areas, such as colorectal, lung, and pancreatic cancers.

Wesley Sukdao, co-founder and CEO of Proteotype Diagnostics shared: “Growing up in poverty in South Africa, I lost three of my closest family members to cancers detected too late, all before I turned fourteen. To meaningfully impact health inequalities, cutting-edge cancer diagnostics must be both affordable and accessible. My team and I are focused to deliver on this mission.”

Driving Cost-Effective Screening for the NHS

Enlighten® does not require highly expensive, specialised equipment or consumables. Affordable laboratory kits applied to crude patient plasma enable easy scale-up for mass screening. With low data requirements and results within 24-hours of sample measurement, it is well positioned for NHS-wide adoption.

MODERNISED will be accompanied by a Health Economic Evaluation to ensure it delivers clinical benefit and meets NHS financial goals.

A Critical Step Forward

This grant is part of a UK Government commitment of £22.5m to deliver the OLS Cancer Programme. The NIHR i4i-OLS call forms part of this programme. Over the next 24-months, Enlighten® will undergo clinical validation, bringing it closer to regulatory approval and potential integration into NHS cancer screening programs.

Professor Andrew Davies, Chief Investigator (MODERNISED), commented: “Enlighten is innovative, capturing changing levels of proteins released into the bloodstream even in the earliest cancer stages. If Enlighten performs well in MODERNISED, it could mark a step change in early cancer diagnostics.”

About Proteotype Diagnostics Ltd

Proteotype is a pioneering diagnostics company dedicated to the development of advanced multi-cancer early detection and personalised medicine tests that measure the host response to tumour development. By leveraging cutting-edge technologies and comprehensive research, Proteotype aims to revolutionise cancer diagnostics and improve early detection, ultimately enhancing patient outcomes and survival rates.

Media contact: pr@proteotype.com 

Email invest@proteotype.com to partner and bring this test to a clinic near you.

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/proteotype-awarded-1-5-million-grant-to-advance-early-cancer-detection-with-innovative-enlighten-test-302271612.html

SOURCE Proteotype Diagnostics

Continue Reading

Technology

DCS Awarded $70.7M Contract to Support Army’s Ground Vehicle Systems Center

Published

on

By

ALEXANDRIA, Va., Oct. 9, 2024 /PRNewswire/ — DCS Corporation is pleased to announce the award of the U.S. Army Combat Capabilities Development Command (DEVCOM) Ground Vehicle Systems Center (GVSC) Ground Vehicle Simulation Lab (GVSL) contract valued at $70.7M.

Under this 5-year contract, DCS will continue to provide technical services to the U.S. Army (DEVCOM) GVSC Immersive Simulation Directorate (GVSC-IS) in Warren, Michigan. GVSC-IS is home to a world-class facility that develops and applies physics-based simulations, simulators, crew station design, and virtual simulation in support of Army ground combat vehicle technology research, development, and maturation. Under this contract, DCS will provide technical services for: Immersive Ground Vehicle Simulation development, integration, and execution; Ride Motion Simulation and Crew Station/Turret Motion Based Simulation; crew station development and integration; and conduct and evaluation of Virtual Experimentation. The technology developed will advance the Army’s ability to evaluate concept and existing vehicle systems mobility, durability, and operations on the move.

“For more than 20 years, DCS has supported GVSC-IS and U.S. Army Tank-Automotive and Armaments Command in conducting motion-based and large-scale experiments at the world-class GVSL modeling and simulation facilities,” commented Bill Protzman, DCS President and COO. “We are excited to continue supporting GVSC-IS and the Warfighter.”

DCS has been a trusted partner of the U.S. Army GVSC and its predecessor organizations for more than 35 years. DCS employee-owners work alongside Government counterparts to further the research, development, acquisition, integration, testing, fielding, and post-fielding operations of manned and unmanned ground vehicles. These Government-contractor teams develop and deliver innovative solutions to support the mission of the Army.

About DCS An employee-owned company, DCS offers advanced technology, engineering, and management solutions to Government agencies in the national security sector. The transformative ideas, commitment to quality, and entrepreneurial spirit that characterize our employee-owners allow us to ensure the success of each customer’s mission and actively contribute to the well-being of the Nation. For more information, please visit: https://www.dcscorp.com

Contact: DCS Media, dcsmedia@dcscorp.com, 571-227-6000

DISTRIBUTION STATEMENT A. Approved for public release; distribution is unlimited. OPSEC9069

View original content to download multimedia:https://www.prnewswire.com/news-releases/dcs-awarded-70-7m-contract-to-support-armys-ground-vehicle-systems-center-302270598.html

SOURCE DCS Corporation

Continue Reading

Trending